Antigen Profiling Platform
We See What the Immune System Sees
Impact Proteomics has built a proprietary antigen resolution and protein identification platform. Impact works directly from patient samples and without cloned intermediates.
Impact Is:
Published in JPR Published in Nature Communications Biology A StartUs Insights Top 5 Biotech A F6S #17 Top US Diagnostic Startup
Our Vision
We are comprehensively mapping disease-associated, antigenic proteins and peptides that the immune system responds to in individuals — and to help translate those insights into diagnostics, drug targets, and therapies that wouldn't otherwise be found. We use our proprietary Impact platform to get there. We work directly from patient samples using natively expressed proteins — resolving the full antigen landscape without predefined targets or cloned intermediates. Proprietary workflows and analysis identify novel antigens from the resolved landscape, delivering actionable targets tailored to the biological question.
The Platform
From Patient Sample to Antigen Profile
A validated, end-to-end workflow using naturally/natively expressed and modified proteins — no cloned genes, manufactured arrays, or specialized equipment.
Step 1
Sample Collection
Patient tissue, cultured cells, and bodily fluids, like serum, plasma
Step 2
Antigen Capture & Sequencing
Proprietary antigen capture & direct mass spectrometric identification
Patented
Step 3
Impact Analysis
Deconvolution of the antigen landscape & target prioritization
Analysis-Powered
Step 4
Antigen Identification
Validated antigen profiles ready for diagnostic, discovery & therapeutic programs
Discuss a Partnership Opportunity
What it Enables
Three High-Value Applications
Applied across the full arc of immune-related drug development and diagnostics.
Companion Diagnostics
Define patient populations with precision. Identify and validate antigen-based biomarkers that stratify cohorts, support companion diagnostic development, and enable monitoring over time — in oncology and autoimmune disease.
Target Discovery
Find targets the field hasn't found yet. Our platform uncovers novel antigens directly from patient samples — neoantigens, tumor-associated antigens, auto-antigens — without the bias of prediction-based approaches.
Therapeutic Identification and Selection
Profile patient-specific antigen landscapes to identify and prioritize the candidates most likely to succeed — antibodies, TCRs, BiTEs, and cell therapy programs — before costly development decisions are made.
"The IP-to-MS technology represents an extremely powerful tool in the assessment of specific humoral immune responses, with applications that range from rheumatic disease to cancer biology. This radiolabel-free approach offers the opportunity to readily detect novel autoantibody autoantigen combinations for improved characterization of immune responses, a process that was previously limited by technical factors associated with conventional immunoprecipitation methods." — Chief of Rheumatology, Leading Autoimmune Research Institution
Discuss a Partnership Opportunity
Whether you are searching for novel targets in a disease area, selecting patients for a therapeutic program, or prioritizing candidates from your existing platform — Impact Proteomics brings the antigen resolution capability to move your program forward. We start by understanding your biological question, then co-design the study, execute the platform workflows, and work with you to interpret what the immune system reveals. The relationship is iterative — we refine the approach as the data builds, and we are structured to grow with your program through co-discovery agreements and milestone-based collaborations.
You can also find us at
